153 related articles for article (PubMed ID: 38403227)
1. Telomerase inhibitors induce mitochondrial oxidation and DNA damage-dependent cell death rescued by Bcl-2/Bcl-xL.
Jayaprasad AG; Chandrasekharan A; Arun Jyothi SP; John Sam SM; Santhoshkumar TR; Pillai MR
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130151. PubMed ID: 38403227
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell redox state and mitochondria at the center of the non-canonical activity of telomerase reverse transcriptase.
Indran IR; Hande MP; Pervaiz S
Mol Aspects Med; 2010 Feb; 31(1):21-8. PubMed ID: 19995569
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
[TBL] [Abstract][Full Text] [Related]
4. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.
Babizhayev MA; Yegorov YE
J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007
[TBL] [Abstract][Full Text] [Related]
5. Non-canonical functions of Telomerase Reverse Transcriptase - Impact on redox homeostasis.
Rosen J; Jakobs P; Ale-Agha N; Altschmied J; Haendeler J
Redox Biol; 2020 Jul; 34():101543. PubMed ID: 32502898
[TBL] [Abstract][Full Text] [Related]
6. Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential.
Shammas MA; Koley H; Batchu RB; Bertheau RC; Protopopov A; Munshi NC; Goyal RK
Mol Cancer; 2005 Jul; 4():24. PubMed ID: 16022731
[TBL] [Abstract][Full Text] [Related]
7. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
8. Intensive inhibition of hTERT expression by a ribozyme induces rapid apoptosis of cancer cells through a telomere length-independent pathway.
Hao ZM; Luo JY; Cheng J; Li L; He D; Wang QY; Yang GX
Cancer Biol Ther; 2005 Oct; 4(10):1098-103. PubMed ID: 16205109
[TBL] [Abstract][Full Text] [Related]
9. Telomerase, checkpoints and cancer.
Harley CB; Sherwood SW
Cancer Surv; 1997; 29():263-84. PubMed ID: 9338104
[TBL] [Abstract][Full Text] [Related]
10. An antiapoptotic role for telomerase RNA in human immune cells independent of telomere integrity or telomerase enzymatic activity.
Gazzaniga FS; Blackburn EH
Blood; 2014 Dec; 124(25):3675-84. PubMed ID: 25320237
[TBL] [Abstract][Full Text] [Related]
11. Treating Cancer by Targeting Telomeres and Telomerase.
Ivancich M; Schrank Z; Wojdyla L; Leviskas B; Kuckovic A; Sanjali A; Puri N
Antioxidants (Basel); 2017 Feb; 6(1):. PubMed ID: 28218725
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis.
Singhapol C; Pal D; Czapiewski R; Porika M; Nelson G; Saretzki GC
PLoS One; 2013; 8(1):e52989. PubMed ID: 23326372
[TBL] [Abstract][Full Text] [Related]
13. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection?
Passos JF; Saretzki G; von Zglinicki T
Nucleic Acids Res; 2007; 35(22):7505-13. PubMed ID: 17986462
[TBL] [Abstract][Full Text] [Related]
14. A high-throughput real-time in vitro assay using mitochondrial targeted roGFP for screening of drugs targeting mitochondria.
Chandrasekharan A; Varadarajan SN; Lekshmi A; Lupitha SS; Darvin P; Chandrasekhar L; Pillai PR; Santhoshkumar TR; Pillai MR
Redox Biol; 2019 Jan; 20():379-389. PubMed ID: 30408753
[TBL] [Abstract][Full Text] [Related]
15. Oxidative damage impact on aging and age-related diseases: drug targeting of telomere attrition and dynamic telomerase activity flirting with imidazole-containing dipeptides.
Babizhayev MA; Vishnyakova KS; Yegorov YE
Recent Pat Drug Deliv Formul; 2014; 8(3):163-92. PubMed ID: 24894799
[TBL] [Abstract][Full Text] [Related]
16. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway.
Massard C; Zermati Y; Pauleau AL; Larochette N; Métivier D; Sabatier L; Kroemer G; Soria JC
Oncogene; 2006 Aug; 25(33):4505-14. PubMed ID: 16619047
[TBL] [Abstract][Full Text] [Related]
17. Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives.
Bilsland AE; Cairney CJ; Keith WN
J Cell Mol Med; 2011 Feb; 15(2):179-86. PubMed ID: 21199331
[TBL] [Abstract][Full Text] [Related]
18. Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy.
Crees Z; Girard J; Rios Z; Botting GM; Harrington K; Shearrow C; Wojdyla L; Stone AL; Uppada SB; Devito JT; Puri N
Curr Pharm Des; 2014; 20(41):6422-37. PubMed ID: 24975605
[TBL] [Abstract][Full Text] [Related]
19. Expression of (NES-)hTERT in cancer cells delays cell cycle progression and increases sensitivity to genotoxic stress.
Kovalenko OA; Kaplunov J; Herbig U; Detoledo S; Azzam EI; Santos JH
PLoS One; 2010 May; 5(5):e10812. PubMed ID: 20520826
[TBL] [Abstract][Full Text] [Related]
20. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
